Literature DB >> 1704369

Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin receptor antagonist.

J P Raufman1, L Singh, J Eng.   

Abstract

Exendin-3 increased cellular cAMP levels and amylase release from dispersed acini from guinea pig pancreas. Low concentrations (0.1-3 nM) caused a 12-fold increase in cAMP, whereas higher concentrations (0.3-3 microM) caused an additional 24-fold increase in cAMP. Maximal cAMP with the highest concentration tested was the same as the maximal response with secretin, vasoactive intestinal peptide (VIP), peptide histidine isoleucine, helodermin, or helospectin-I. In terms of amylase release, exendin-3 had the same efficacy but was the least potent of these peptides. Exendin-3-induced increases in amylase release were inhibited by VIP receptor antagonists and the new peptide (greater than 0.1 microM) competed with radiolabeled VIP for binding sites on dispersed acini. Increasing concentrations of an exendin-3 fragment, exendin-3(9-39) amide, did not increase cAMP or amylase release but inhibited the increase in cAMP observed with 0.1-3 nM exendin-3. The fragment did not alter the effects of other peptides that are known to increase acinar cAMP. We conclude that exendin-3 interacts with at least two receptors on guinea pig pancreatic acini; at high concentrations (greater than 100 nM) the peptide interacts with VIP receptors, thereby causing a large increase in cAMP and stimulating amylase release; at lower concentrations (0.1-3 nM) the peptide interacts with a putative exendin receptor, thereby causing a smaller increase in cAMP of undetermined function. Exendin-3(9-39) amide is a specific exendin receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704369

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 3.  Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors:  J J Holst
Journal:  Diabetologia       Date:  2006-01-14       Impact factor: 10.122

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.

Authors:  Maarten Brom; Lieke Joosten; Wim J G Oyen; Martin Gotthardt; Otto C Boerman
Journal:  Contrast Media Mol Imaging       Date:  2012 Mar-Apr       Impact factor: 3.161

6.  Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms.

Authors:  Marion L Vetter; Scott Ritter; Thomas A Wadden; David B Sarwer
Journal:  Diabetes Spectr       Date:  2012-11-01

Review 7.  The Role of Incretins on Insulin Function and Glucose Homeostasis.

Authors:  Jens Juul Holst; Lærke Smidt Gasbjerg; Mette Marie Rosenkilde
Journal:  Endocrinology       Date:  2021-07-01       Impact factor: 4.736

8.  Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.

Authors:  A H Sparre-Ulrich; L S Hansen; B Svendsen; M Christensen; F K Knop; B Hartmann; J J Holst; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2015-11-20       Impact factor: 8.739

9.  Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

Authors:  Nils B Jørgensen; Carsten Dirksen; Kirstine N Bojsen-Møller; Siv H Jacobsen; Dorte Worm; Dorte L Hansen; Viggo B Kristiansen; Lars Naver; Sten Madsbad; Jens J Holst
Journal:  Diabetes       Date:  2013-05-06       Impact factor: 9.461

10.  GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification.

Authors:  Marion L Vetter; Thomas A Wadden; Karen L Teff; Zahra F Khan; Raymond Carvajal; Scott Ritter; Reneé H Moore; Jesse L Chittams; Alex Iagnocco; Kenric Murayama; Gary Korus; Noel N Williams; Michael R Rickels
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.